21 Oct 2025 | 5 Mins Read
Laurus Labs poised for significant growth, analyst predicts
Flipitmoney
B&K Securities initiated coverage on Laurus Labs with a 'Buy' recommendation and a ₹1,030 price target, implying an 18% potential upside from Monday's closing level. The brokerage cites Laurus Labs' high-margin CDMO franchise and sustained 40% revenue CAGR in small molecules as key drivers. The stock trades at 38.6x FY28E EPS, justifying elevated valuations.